Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Inclusion Criteria:

• Male or female ≥ 18 years

• Type 2 Diabetes Mellitus

• Hemoglobin A1c < 10%

• Stable diabetes therapy

• Must be on maximally tolerated dose of statin of at least moderate Intensity

• Fasting triglycerides ≤ 600 mg/dL

• Not at LDL-C or Non-HDL-C goal.

Exclusion Criteria:

• Moderate to severe renal dysfunction

• Uncontrolled hypertension

• Persistent active liver disease or hepatic dysfunction

• Has taken a cholesterylester transfer protein inhibitor in the last 12 months,

• Myocardial infarction, unstable angina, percutaneous coronary intervention, coronaryartery bypass graft or stroke within 3 months prior to randomization